Evidence map›Paper›PMID 35382429›Full record

ArticleEuropean journal of operational research2022

Designing an optimal sequence of non-pharmaceutical interventions for controlling COVID-19.

Debajyoti Biswas, Laurent Alfandari

Open access · greenAbstract read
In one paragraph

Article in European journal of operational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Debajyoti BiswasESSEC Business School, Cergy 95000, France.
Laurent AlfandariESSEC Business School, Cergy 95000, France.
CY Cergy Paris Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has had an unprecedented impact on global health and the economy since its inception in December, 2019 in Wuhan, China. Non-pharmaceutical interventions (NPI) like lockdowns and curfews have been deployed by affected countries for controlling the spread of infections. In this paper, we develop a Mixed Integer Non-Linear Programming (MINLP) epidemic model for computing the optimal sequence of NPIs over a planning horizon, considering shortages in doctors and hospital beds, under three different lockdown scenarios. We analyse two strategies - centralised (homogeneous decisions at the national level) and decentralised (decisions differentiated across regions), for two objectives separately - minimization of infections and deaths, using actual pandemic data of France. We linearize the quadratic constraints and objective functions in the MINLP model and convert it to a Mixed Integer Linear Programming (MILP) model. A major result that we show analytically is that under the epidemic model used, the optimal sequence of NPIs always follows a decreasing severity pattern. Using this property, we further simplify the MILP model into an Integer Linear Programming (ILP) model, reducing computational time up to 99%. Our numerical results show that a decentralised strategy is more effective in controlling infections for a given severity budget, yielding up to 20% lesser infections, 15% lesser deaths and 60% lesser shortages in healthcare resources. These results hold without considering logistics aspects and for a given level of compliance of the population.

Indexed as

COVID-19Integer programmingNon-Pharmaceutical interventionsOR in healthcareScheduling

Identifiers

PMID35382429
PMCPMC8970617
OpenAlexW4220741352

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.